Redpin debuts chemogenetic platform for neurology, raises $15.5M

Redpin aims to tamp down neuron excitability with its conditionally active ion channels

Redpin emerged from stealth Wednesday with a $15.5 million series A round and a chemogenetics platform designed to treat neurological disorders by controlling neuron excitability.

4Bio Capital and Arkin Bio Ventures led the tranched round. New investor Takeda Ventures Inc. also participated, as did existing investors New York Ventures and Alexandria Venture Investments.

“Chemogenetics is a way of controlling cellular activity by introducing an exogenous receptor into a specific cell population,” Redpin co-founder, President and CEO Elma Hawkins told BioCentury.

Founded in 2017, Redpin Therapeutics

Read the full 836 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers